Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. 2010

Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
Pharmacokinetics Dynamics and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut 06340, USA. manthena.v.varma@pfizer.com

Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh). In this study, using a database comprised of Fa, Fg, Fh, and F values for 309 drugs in humans, an analysis of the interrelation of physicochemical properties and the individual parameters was carried out in order to define the physicochemical space for optimum human oral bioavailability. Trend analysis clearly indicated molecular weight (MW), ionization state, lipophilicity, polar descriptors, and free rotatable bonds (RB) influence bioavailability. These trends were due to a combination of effects of the properties on Fa and first-pass elimination (Fg and Fh). Higher MW significantly impacted Fa, while Fg and Fh decreased with increasing lipophilicity. Parabolic trends were observed for bioavailability with polar descriptors. Interestingly, RB has a negative effect on all three parameters, leading to its pronounced effect on bioavailability. In conclusion, physicochemical properties influence bioavailability with typically opposing effects on Fa and first-pass elimination. This analysis may provide a rational judgment on the physicochemical space to optimize oral bioavailability.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
March 2011, Xenobiotica; the fate of foreign compounds in biological systems,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
April 1996, Biological & pharmaceutical bulletin,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
December 1997, Drug metabolism and disposition: the biological fate of chemicals,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
January 1989, Drug metabolism and disposition: the biological fate of chemicals,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
August 2014, Drug development and industrial pharmacy,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
January 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
August 2007, Drug metabolism and disposition: the biological fate of chemicals,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
December 1977, Clinical pharmacology and therapeutics,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
March 1997, Clinical pharmacology and therapeutics,
Manthena V S Varma, and R Scott Obach, and Charles Rotter, and Howard R Miller, and George Chang, and Stefanus J Steyn, and Ayman El-Kattan, and Matthew D Troutman
July 1980, Journal of pharmaceutical sciences,
Copied contents to your clipboard!